Gilead Sciences (GILD) Stock: Analyst Believes New CEO Could Be a Game-Changer

Congrats! Gilead Sciences (GILD) has just appointed Daniel O’Day as the Chief Executive Officer of the pharmaceutical giant.

J.P. Morgan Weighs in on Sangamo Therapeutics Inc’s (SGMO) Collaboration with Kite

Sangamo Therapeutics Inc (NASDAQ:SGMO) has just announced a strategic collaboration with Gilead Sciences, Inc’s (NASDAQ:GILD) company Kite, and shares are putting together a massive …

Gilead Sciences’ HIV Franchise Is Poised to Recapture Share, Says Senior Analyst Phil Nadeau

Gilead Sciences, Inc. (NASDAQ:GILD), which built its reputation on turning HIV drug cocktails into easy-to-use, daily, single-pill regimens, announced today that the FDA has approved …

Gilead Sciences, Inc. Notches FDA Approval for Biktarvy in HIV-1

In a landmark advancement against the onslaught of AIDS, the FDA approved today a once-daily single tablet regimen (STR) of Gilead Sciences (NASDAQ:GILD), as a complete …

Sing Hallelujah! Gilead Sciences, Inc. Shares Are on the Move; Oppenheimer Weighs In

Oppenheimer’s Hartaj Singh notes that Gilead outperformed his 4Q expectations, but continues to play it safe on the giant.

Teva Pharmaceutical Launches First Generic Formulation of Gilead’s Blockbuster Antiretroviral Truvada

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced this morning the exclusive US launch of Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg, a generic …

Jason Kolbert Is Confident Gilead Sciences, Inc. (GILD) Can Resolve Any Yescarta Patient Backlog Challenges

Though Yescarta launch has seen patients condemned to waiting lists, Maxim’s Jason Kolbert is “inspired” by GILD’s global plan to commercialize the drug.

Jason McCarthy’s Take on Gilead Sciences, Inc. (GILD) Following ASH Data

ASH data offers insight into Gilead Sciences’ lymphoma drug Yescarta; Maxim’s Jason McCarth weighs in.